Stephanie Samuels, MD
Assistant ProfessorCards
About
Research
Publications
2025
Biomarkers of Glycolysis and the Tricarboxylic Acid Cycle in Youth with and without Obesity
Refugjati E, Li Z, Umano G, Galuppo B, Van Name M, Samuels S, Kang G, Barbieri E, Hwang J, Santoro N. Biomarkers of Glycolysis and the Tricarboxylic Acid Cycle in Youth with and without Obesity. Hormone Research In Paediatrics 2025, 1-6. PMID: 41411205, PMCID: PMC12749259, DOI: 10.1159/000548624.Peer-Reviewed Original ResearchProton-density fat fractionPlasma concentrationsMetabolic consequencesInsulin resistancePrevalence of childhood obesityAdipose tissue insulin resistanceTissue insulin resistanceType 2 diabetesDevelopment of insulin resistanceLiver proton-density fat fractionExcess adiposityMetabolomic analysisChildhood obesityLevels of glucoseMetabolic dysregulationObesityPlasma concentrations of lactateCardiovascular diseaseFat fractionTricarboxylic acidConcentrations of lactateGlucose utilizationYoung adultsTricarboxylic acid cycle intermediatesAdipose
2024
Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imagingImproving access to first‐line treatment for pediatric obesity: Lessons from the dissemination of SmartMoves
Finn E, Keller C, Gowey M, Savoye M, Samuels S, Fleisch A, Rogers V, Grey M, Damschroder L, Beck A, Sharifi M. Improving access to first‐line treatment for pediatric obesity: Lessons from the dissemination of SmartMoves. Obesity 2024, 32: 1745-1756. PMID: 39192771, PMCID: PMC11875074, DOI: 10.1002/oby.24107.Peer-Reviewed Original ResearchConceptsConstant comparative methodInterviewed key informantsHealth behaviorsObesity programsSufficient staffingInsufficient staffingPediatric obesityFunding insecurityLifestyle treatmentImprove accessOrganizational prioritiesProgram componentsProgram fitPromote fidelityKey informantsUS sitesIncreased prevalenceAdequate fundingSurvey findingsStaffingParticipantsInterviewsCOVID-19 pandemicDominant barriersObesityOverview of the Treatment of Pediatric Obesity and the 2023 Clinical Practice Guidelines
Hu P, Samuels S, Sharifi M. Overview of the Treatment of Pediatric Obesity and the 2023 Clinical Practice Guidelines. Pediatric Clinics Of North America 2024, 71: 919-926. PMID: 39343501, DOI: 10.1016/j.pcl.2024.06.005.ChaptersReal‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAFollow-upType 2 diabetesReceptor agonistsGLP-1RAsDiverse cohort of youthEffects of glucagon-like peptide-1 receptor agonistsBody mass index z-scoreMedian Follow-UpMulticentre retrospective studyReduced insulin doseGLP-1RA treatmentPatients prescribed insulinFollow-up visitAssociated with short-term improvementsPaediatric diabetes centresManagement of type 2 diabetesManagement of T2DMetformin regimenBMI-zMedian HbA1cRetrospective studyDosing frequency
2023
1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis
SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.Peer-Reviewed Original ResearchGlucagon-like-peptide-1 agonistsFollow-upAmerican Diabetes AssociationType 2 diabetesManagement of T2DDiverse cohort of youthReduced doses of insulinMonths of follow-upMulticenter retrospective analysisGlucagon-like-peptide-1High risk of diabetic complicationsGLP-1 agonistsRisk of diabetic complicationsDoses of insulinPediatric diabetes centersBaseline to follow-upAssociated with improvementsMetformin usePharmacological optionsReduced dosePediatric populationPrandial insulinPrescribed metforminRetrospective analysisNational Institutes of HealthComparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity
Galuppo B, Umano G, Li Z, Van Name M, Samuels S, Kien C, Cline G, Wagner D, Barbieri E, Tricò D, Santoro N. Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity. JAMA Network Open 2023, 6: e2312530. PMID: 37159195, PMCID: PMC10170343, DOI: 10.1001/jamanetworkopen.2023.12530.Peer-Reviewed Original ResearchConceptsInsulin sensitivity indexCross-sectional studyFree fatty acidsColonic fermentationActive glucagon-like peptide-1Plasma free fatty acidsGlucagon-like peptide-1Indigestible dietary carbohydratesReduction of ghrelinActive GLP-1Health care burdenBody mass indexMetabolic responseInsulin-resistant groupLean youthObese insulinOIS groupPYY responseAnorexigenic responsePediatric obesityMass indexTyrosine tyrosineInsulin resistanceIntravenous infusionHormone secretionRising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States
Slusher A, Hu P, Samuels S, Tokoglu F, Lat J, Li Z, Alguard M, Strober J, Vatner D, Shabanova V, Caprio S. Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States. Obesity 2023, 31: 1383-1391. PMID: 36694381, PMCID: PMC10186584, DOI: 10.1002/oby.23728.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseOral glucose tolerance testGlucose tolerance testProton density fat fractionLiver diseaseSARS-CoV-2 pandemicTolerance testSeverity of NAFLDMagnetic resonance imaging-derived proton density fat fractionFrequency-matched control groupIntrahepatic fat contentCommon liver diseaseFatty liver diseasePediatric obesity clinicVisceral adipose tissueGlobal pandemicNAFLD prevalenceObesity clinicMetabolic severityInsulin secretionAdipose tissueControl groupObesityPatient careHealth differences
2022
Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity
Samuels S, Hu P, Maciejewski K, Li F, Dziura J, Savoye M, Sharifi M. Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity. Obesity 2022, 31: 203-213. PMID: 36502287, PMCID: PMC9780185, DOI: 10.1002/oby.23627.Peer-Reviewed Original ResearchConceptsPediatric weight management interventionsHealthy lifestyle interventionReal-world effectivenessWeight management interventionsLifestyle interventionChildhood obesityClinical effectivenessFemale sexInsurance categoriesBMIp95Mixed-effects modelsGreater reductionBMIBright bodiesInterventionSexParticipantsManagement interventionsObesityReal-world adaptationYearsTrialsMechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach
Tricò D, McCollum S, Samuels S, Santoro N, Galderisi A, Groop L, Caprio S, Shabanova V. Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach. Diabetes Care 2022, 45: 1841-1851. PMID: 35766976, PMCID: PMC9346992, DOI: 10.2337/dc22-0110.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell functionΒ-cell glucose sensitivityInsulin sensitivityGenetic risk profileMultiple oral glucose tolerance testsDifferent genetic risk profilesRisk profileMin oral glucose tolerance testLatent class trajectory analysisGlucose tolerance testImpaired insulin sensitivityPlasma glucose responseGlucose sensitivityClass 3Model-predicted probabilityClass 1Tolerance testProgressive impairmentMultiethnic cohortGlucose responseLongitudinal changesObesityTransient reductionInsulin kinetics
Clinical Trials
Current Trials
Are you aged 18-30 with Type 1 diabetes and a body mass index ≥27kg/m2?
IRB ID2000035452RoleSub InvestigatorPrimary Completion Date06/30/2028Recruiting ParticipantsPhysiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
IRB ID2000036125RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsSemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
IRB ID2000031181RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsPathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Youth with Obesity
IRB ID2000028731RoleSub InvestigatorPrimary Completion Date08/31/2025Recruiting ParticipantsGenderBothAge12 years - 22 yearsThe Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis
IRB ID1604017607RoleSub InvestigatorPrimary Completion Date05/01/2023Recruiting ParticipantsGenderBothAge12 years - 30 years
Clinical Care
Overview
Clinical Specialties
Pediatric Endocrinology & Diabetes
Fact Sheets
Psychological Assessment of Children
Learn More on Yale MedicineChild Development
Learn More on Yale MedicineHyperglycemia: Symptoms, Causes, and Treatments
Learn More on Yale MedicineHemoglobin A1C Test
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.